This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial


de Yebenes, Justo Garcia, Landwehrmeyer, Bernhard, Squitieri, Ferdinando, Reilmann, Ralf, Rosser, Anne, Barker, Roger A, Saft, Carsten, Magnet, Markus K., Sword, Alastair, Rembratt, Åsa, Tedroff, Joakim


The Lancet. Neurology, Volume: 10, No.: 12, Pages.: 1049-1057

Year of Publication



Background: Huntington’s disease is a progressive neurodegenerative disorder, characterised by motor, cognitive, and behavioural deficits. Pridopidine belongs to a new class of compounds known as dopaminergic stabilisers, and results from a small phase 2 study in patients with Huntington’s disease suggested that this drug might improve voluntary motor function. We aimed to assess further the effects of pridopidine in patients with Huntington’s disease.; Methods: We undertook a 6 month, randomised, double-blind, placebo-controlled trial to assess the efficacy of pridopidine in the treatment of motor deficits in patients with Huntington’s disease. Our primary endpoint was change in the modified motor score (mMS; derived from the unified Huntington’s disease rating scale) at 26 weeks. We recruited patients with Huntington’s disease from 32 European centres; patients were aged 30 years or older and had an mMS of 10 points or greater at baseline. Patients were randomly assigned (1:1:1) to receive placebo, 45 mg per day pridopidine, or 90 mg per day pridopidine by use of centralised computer-generated codes. Patients and investigators were masked to treatment assignment. We also assessed the safety and tolerability profile of pridopidine. For our primary analysis, all patients were eligible for inclusion in our full analysis set, in which we used the last observation carried forward method for missing values. We used an analysis of covariance model and the Bonferroni method to adjust for multiple comparisons. We used a prespecified per-protocol population as our sensitivity analysis. The α level was 0·025 for our primary analysis and 0·05 overall. This trial is registered with, number NCT00665223.; Findings: At 26 weeks, in our full analysis set the difference in mean mMS was -0·99 points (97·5% CI -2·08 to 0·10, p=0·042) in patients who received 90 mg per day pridopidine (n=145) versus those who received placebo (n=144), and -0·36 points (-1·44 to 0·72, p=0·456) in those who received 45 mg per day pridopidine (n=148) versus those who received placebo. At the 90 mg per day dose, in our per-protocol population (n=114), the reduction in the mMS was of -1·29 points (-2·47 to -0·12; p=0·014) compared with placebo (n=120). We did not identify any changes in non-motor endpoints at either dose. Pridopidine was well tolerated and had an adverse event profile similar to that of placebo.; Interpretation: This study did not provide evidence of efficacy as measured by the mMS, but a potential effect of pridopidine on the motor phenotype of Huntington’s disease merits further investigation. Pridopidine up to 90 mg per day was well tolerated in patients with Huntington’s disease.; Funding: NeuroSearch A/S.; Copyright © 2011 Elsevier Ltd. All rights reserved.

Bibtex Citation

@article{de_Yebenes_2011, doi = {10.1016/s1474-4422(11)70233-2}, url = {}, year = 2011, month = {dec}, publisher = {Elsevier {BV}}, volume = {10}, number = {12}, pages = {1049--1057}, author = {Justo Garcia de Yebenes and Bernhard Landwehrmeyer and Ferdinando Squitieri and Ralf Reilmann and Anne Rosser and Roger A Barker and Carsten Saft and Markus K Magnet and Alastair Sword and {AA}sa Rembratt and Joakim Tedroff}, title = {Pridopidine for the treatment of motor function in patients with Huntington{textquotesingle}s disease ({MermaiHD}): a phase 3, randomised, double-blind, placebo-controlled trial}, journal = {The Lancet Neurology} }


adult, aged, double-blind method, drug effects, drug therapy, female, humans, huntington disease, male, middle aged, modified, motor, motor activity, pharmacology, piperidines, pridopidine, score, therapeutic use, treatment outcome

Countries of Study


Types of Dementia


Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions